Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,704 total articles
Qualys trades at a premium multiple today but shows signs that a stronger product roadmap and sustained cloud-security demand could justify the valuation. This trade idea lays out a long entry, precise risk controls, catalysts to watch and the scenarios that would make us change our view.
G Mining (GMINF) is trading near $38.43 with a $11.40B market cap and a P/E of 24.8. Balance-sheet strength and recent operational scale-up position the company to pursue sizable expansion. Technicals are constructive and short interest is meaningful — a controlled long with a $50 target and $33 stop balances upside from expansion against execution…
Summit Midstream looks poised for a material re-rating as leverage comes down and EBITDA shows sequential improvement. With clear operational levers and identifiable catalysts, a controlled long trade offers a favorable reward-to-risk setup. Entry at $6.50, stop at $5.25, target at $9.25 over a 180 trading-day horizon.
Onto Innovation supplies metrology, inspection, lithography and yield-management tools that are becoming critical as AI chips scale. The stock has pulled back ~20% from its prior close and shows technical signs of a consolidation; we argue this is a buy-the-dip setup for a mid-term swing trade targeting higher multiple re-rating as customers priori…
Allogene trades like a binary biotech with limited upside priced in. Recent arbitration wins, durable responses from ALLO-316, and a $175M capital raise create a window where upside from commercialization or partnership of cema-cel could re-rate the stock. This trade idea lays out a long position at $2.02 with clear stops, targets, catalysts and ri…
Septerna is an early-stage biotech focused on GPCR-targeted therapies. Clinical and translational data remain the key value drivers; with limited public financial detail available, the upside hinges on program validation, partnering potential, and platform durability. I am long and recommend an entry at $6.50 with a $15.00 target and a $3.50 stop f…
PennyMac Mortgage Investment Trust (PMT) could spike on positive headlines, but the firm's economics - thin capital buffers, a high yield priced for risk, and uneven cash flow dynamics - mean the victory probably won't change the core valuation. I recommend a mid-term short trade: enter on strength, keep a disciplined stop, and target a fade toward…
MasTec's recent acceleration in revenue and earnings, combined with exposure to AI-related power buildouts and a strategic addition (Superior), creates an asymmetric risk/reward on pullbacks. Valuation is elevated at a ~40x P/E, but cash flow generation, a manageable balance sheet and visible contract demand support a swing trade entry with defined…
TC Energy (TRP) is a cash-generating pipeline and power operator with a 4.0% yield and a capital structure built for regulated midstream returns. With natural gas remaining the flexible baseload for data-center and AI workloads, TRP offers a pragmatic swing trade: buy near-term weakness with a defined stop and a target below the 52-week high. Techn…
BioNTech (BNTX) is a buy here. The company sits at the intersection of two durable growth vectors: ongoing commercialization and variant-adaptation of COMIRNATY (its mRNA vaccine franchise) and an accelerating late-stage oncology pipeline. At a market cap of ~$25.6B and a stock trading near $102, upside to our $150 target looks achievable over a 18…
Encompass Health (EHC) is the largest U.S. inpatient rehabilitation operator with steady free cash flow, improving reimbursement dynamics, and an earnings beat that lifted guidance. The combination of a modest valuation (EV/EBITDA ~9.2), raised guidance, and a scheduled Medicare rate increase supports a mid-term bullish trade while remaining mindfu…
Lantronix (LTRX) just moved into my buy box. New product rollouts, strategic partnerships and a broadly healthy balance sheet make the equity a compelling mid-term swing trade. I outline an entry at $5.50, a stop at $4.50 and a target at $8.75 over a 45-trading-day horizon, plus the risks and catalysts that could change the thesis.
Salesforce's new strategic tie-up with Anthropic and a $5.1B stake that just booked a $2.7B unrealized gain repositions the company from SaaS incumbent to an AI platform gatekeeper. Q2 results beat, raised guidance and early monetization metrics create a credible growth runway. This trade plan buys the narrative with a disciplined stop and a 180-tr…
Appian is showing signs of product-market fit in the AI era: cloud revenue acceleration, margin expansion, and positive free cash flow combine with technical momentum. I recommend a disciplined long entry at $42.00, stop at $37.00 and a primary target of $55.00 over a mid-term (45 trading days) horizon. Trade size should be sized to risk tolerance;…
Tesla's hardware-first investments in autonomy are beginning to generate measurable revenue streams (robotics, Semi, FSD), and current sell-off has created an actionable risk/reward for a mid-term long. Balance lofty multiples against clear early cash conversion and near-term catalysts like the Semi event (09/24/2026) and Optimus production ramp.
<p>Bunge (BG) remains my preferred way to play steady global food and protein demand. The stock's recent pullback offers a reasonably priced entry while the company levers scale from its agribusiness and oils franchises and returns cash through a sizable buyback program. I upgrade to Buy and lay out a trade plan below with precise entry, stop and t…
BILL is showing the kind of operational progress investors asked for: steady revenue growth, strong free cash flow, and a valuation that no longer assumes runaway top-line growth. For traders willing to be patient and disciplined, a mid-term bullish trade captures upside to the 52-week high while limiting downside if execution slips.
Micron has moved from cyclical to structural tailwinds after a wave of AI infrastructure spending. Recent industry commentary and Micron's own margin print (84.9% non-GAAP gross in Q3) make the company's AI exposure increasingly tangible. With a $1.04T market cap, robust free cash flow and an attractive payoff vs. downside, I lay out a long trade w…
AT&T is trading at single-digit multiples with a hefty dividend and improving technicals. Strong free cash flow ($13.3B trailing), low P/E (8.4x) and an EV/EBITDA of 6.5x leave room for re-rating if revenue and margin stabilization continue. This trade idea lays out a concrete entry, stop and target with timeframes and the key risks that could dera…
AXT (AXTI) has transformed from a microcap substrate maker into the dominant supplier of indium phosphide (InP) wafers used in photonics and AI data-center optics. The market is pricing rapid growth and supply tightness into a rich valuation. This trade idea argues the current pullback is an actionable long with clear entry, stop and target while a…
Nvidia reported results that keep its AI leadership intact and secured a sizable AWS GPU commitment. I’m doubling my exposure with a clearly defined entry at $220.16, a stop at $200.00 and a target of $264.00 over the next 180 trading days. The setup mixes strong fundamentals, near-term catalysts and manageable technical risk — but valuation and ex…
SpaceX is deploying capital raised via debt to scale Starlink and build AI-optimized edge and data-center infrastructure. Public market access is limited, but secondary liquidity and structured products exist. This trade is a high-conviction, risk-managed long: enter at $250.00, stop at $200.00, target $350.00 over a 180 trading day horizon. The th…
BioCryst combines a profitable, growing oral HAE franchise (ORLADEYO) with a late-stage monoclonal antibody (navenibart) that could capture patients who prefer infrequent injections. The balance sheet and licensing proceeds materially de-risk near-term funding. With free cash flow of ~$373M and 2026 ORLADEYO guidance intact, the stock at $9.72 offe…
SK hynix appears to combine stronger recent revenue traction than Micron with a valuation discount that the market has not fully priced in. We initiate a buy with clear entry, target and stop levels and a preference for a medium-term hold to capture cyclical recovery and product-cycle tailwinds.
Pinterest is trading like ad revenue has already collapsed and user engagement will never recover. Recent ARPU gains, robust free cash flow of $1.28B, and a manageable balance sheet argue for a tactical long. This trade targets a rebound toward $30 over the next 45 trading days with a disciplined $20 stop.
